Also listed under Muscular Dystrophies
ClinicalTrials.gov term: Muscular Dystrophy, Duchenne
Duchenne Muscular Dystrophy clinical trials
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-06
What changed in the last 30 days
14 trials changed in the last 30 days: 0 stopped, 7 with notable changes, 7 with minor changes only.
- Notable: Dystrophin Expression of SPOT-03 in Duchenne Muscular Dystrophy (DMD) Patients Primary and study completion pushed from Dec 2026 to Dec 2028
- Minor: EVOLVE · Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practice Trial sites expanded: 20 → 23 locations
- Minor: GRASP-01-002 · Defining Endpoints in Becker Muscular Dystrophy Trial completed
- Minor: Extracellular RNA Biomarkers of Duchenne Muscular Dystrophy Enrollment closed, study ongoing
- Minor: ARNseq-Musc · Transcriptomic Analysis to Put an End to Misdiagnosis · Rare Muscle Diseases Primary completion pushed from Sep 1, 2026 to Dec 1, 2026
- Notable: Tadalafil as Adjuvant Therapy for DMD Results posted: Oct 27, 2026
- Notable: ENDURE · Delandistrogene Moxeparvovec (ELEVIDYS) With Standard of Care · Duchenne Muscular Dystrophy Primary completion moved earlier from Dec 31, 2029 to Dec 31, 2028
- Minor: DANNIgene · Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders Study completion pushed from May 2027 to Jun 2028
- Minor: WVE-N531 · Duchenne Muscular Dystrophy (FORWARD-53) Enrollment closed, study ongoing
- Minor: IGNITE DMD · Microdystrophin Gene Transfer Study in Adolescents and · DMD Primary and study completion pushed from Oct 15, 2026 to Nov 30, 2026
- Notable: SEE-NMD · Self-Efficacy Enhancement Among Online Support Group of Primary Caregivers · Neuro Muscular Dystrophy Primary completion pushed from Mar 23, 2026 to Nov 20, 2026
- Notable: VM100 Nutritional Supplement for Improving Quality of Life in Duchenne Muscular Dystrophy Patients Phase changed: Not applicable → Phase 2
- Notable: Ataluren · Nonsense Mutation Dystrophinopathy (nmDBMD) Reclassified as terminated (was completed)
- Notable: FAIR-DMD · Registry for Duchenne and Becker Muscular Dystrophy Recruitment opened
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
New sponsor entrants, last 90 days sponsors with their first trial in this area
| First posted | Trial | Sponsor | Phase |
|---|---|---|---|
| 2026-10-23 | NCT07892196 Does Chronic Pain Change Over Time in Children With Duchenne Muscular Dystrophy? | Antalya Training and Research Hospital new | |
| 2026-10-19 | NCT07879989 Respiratory Progression in Adults With Duchenne Muscular Dystrophy. | Istituto Giannina Gaslini new | |
| 2026-08-26 | NCT07787689 Intermittent vs Alternate Daily Regimen of Prednisolone in Ambulatory Boys With Duchenne… | Muhammad Aamir Latif new |
Active trials by phase
| Early Phase 1 | 6 | |
| Phase 1 | 6 | |
| Phase 1/2 | 12 | |
| Phase 2 | 21 | |
| Phase 2/3 | 3 | |
| Phase 3 | 9 | |
| Phase 4 | 4 |
Not charted: 74 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Top sponsors by active trials in this area
Sarepta Therapeutics, Inc. (7) · Lokman Hekim University (6) · Vanderbilt University Medical Center (5) · Centre Hospitalier Universitaire de Liege (3) · Entrada Therapeutics, Inc. (3) · Italfarmaco (3) · NS Pharma, Inc. (3) · Peking Union Medical College Hospital (3) · REGENXBIO Inc. (3) · Solid Biosciences Inc. (3)
Get alerts when Duchenne Muscular Dystrophy trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.